AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8105673 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-out intervention program
Number of subjects: 450
Study 8105673 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 450
Study 3541824 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, 150 mg daily
Number of subjects: 20
Study 3541824 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, 100 mg daily
Number of subjects: 20
Study 3541824 — intervention group
Group type: COMPARATOR
Intervention: Drug-free control day
Number of subjects: 20
Study 29461600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF) at 50-100 ml/kg/h
Number of subjects: 76
Study 29461600 — intervention group
Group type: COMPARATOR
Intervention: Conventional volume hemofiltration at 35-50 ml/kg/h
Number of subjects: 76
Study 27475262 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg once daily
Number of subjects: 22
Study 27475262 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/Aliskiren combination
Number of subjects: 22
Study 27475262 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily
Number of subjects: 22
Study 27475262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24052631 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paricalcitol (1 μg one time daily)
Number of subjects: 60
Study 24052631 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 60
Study 23322425 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast plus LABA
Number of subjects: 0
Study 23322425 — intervention group
Group type: COMPARATOR
Intervention: LABA monotherapy
Number of subjects: 0
Study 20500273 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative face‐to‐face counselling about active preoperative nutrition
Number of subjects: 116
Study 20500273 — intervention group
Group type: COMPARATOR
Intervention: Current practice instructions (Control)
Number of subjects: 116
Study 18167171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact soya protein (SPI)
Number of subjects: 24
Study 18167171 — intervention group
Group type: COMPARATOR
Intervention: Soya protein hydrolysate (SPH)
Number of subjects: 24
Study 18167171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact whey protein (WPI)
Number of subjects: 24
Study 18167171 — intervention group
Group type: COMPARATOR
Intervention: Whey protein hydrolysate (WPH)
Number of subjects: 24
Study 15851891 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg lidocaine infused over 30 min
Number of subjects: 24
Study 15851891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12777634 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery in lcSSc patients
Number of subjects: 73
Study 12777634 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery in dcSSc patients
Number of subjects: 73
Study 12777634 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery in control subjects
Number of subjects: 73
Study 12777634 — intervention group
Group type: COMPARATOR
Intervention: Femoral artery in lcSSc patients
Number of subjects: 73
Study 12777634 — intervention group
Group type: COMPARATOR
Intervention: Femoral artery in dcSSc patients
Number of subjects: 73
Study 12777634 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral artery in control subjects
Number of subjects: 73
Study 12777634 — intervention group
Group type: COMPARATOR
Intervention: Intima-media thickness (IMT) of carotid artery in lcSSc patients
Number of subjects: 73
Study 12777634 — intervention group
Group type: COMPARATOR
Intervention: Intima-media thickness (IMT) of carotid artery in dcSSc patients
Number of subjects: 73
Study 12777634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intima-media thickness (IMT) of carotid artery in control subjects
Number of subjects: 73
Study 12777634 — intervention group
Group type: COMPARATOR
Intervention: Intima-media thickness (IMT) of femoral artery in lcSSc patients
Number of subjects: 73
Study 12777634 — intervention group
Group type: COMPARATOR
Intervention: Intima-media thickness (IMT) of femoral artery in dcSSc patients
Number of subjects: 73
Study 12777634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intima-media thickness (IMT) of femoral artery in control subjects
Number of subjects: 73
Study 10562779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine (4% solution, 4 ml)
Number of subjects: 15
Study 10562779 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline
Number of subjects: 15
Study 10562779 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent period assessment
Number of subjects: 15
Study 8882840 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined vignettes
Number of subjects: 60
Study 8882840 — intervention group
Group type: COMPARATOR
Intervention: Viewed vignettes
Number of subjects: 60
Study 8882840 — intervention group
Group type: EXPERIMENTAL
Intervention: Blatantly racist material
Number of subjects: 60
Study 8882840 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtle forms of racism
Number of subjects: 60
Study 15374363 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 45 mg/day b.i.d. for 120 days
Number of subjects: 108
Study 15374363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 6405773 — intervention group
Group type: COMPARATOR
Intervention: Dexamphetamine 5 mg
Number of subjects: 12
Study 6405773 — intervention group
Group type: COMPARATOR
Intervention: Dexamphetamine 10 mg
Number of subjects: 12
Study 6405773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 100 mg
Number of subjects: 12
Study 6405773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 200 mg
Number of subjects: 12
Study 6405773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine 100 mg
Number of subjects: 12
Study 6405773 — intervention group
Group type: COMPARATOR
Intervention: Lactose dummy
Number of subjects: 12
Study 31609021 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient multicomponent occupational rehabilitation including physical activity (PA)
Number of subjects: 265
Study 31609021 — intervention group
Group type: COMPARATOR
Intervention: Outpatient program without physical activity (PA)
Number of subjects: 265
Study 31609021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased vigorous physical activity
Number of subjects: 265
Study 31609021 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently high intensity of physical activity
Number of subjects: 265
Study 31609021 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity physical activity
Number of subjects: 265
Study 30428122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of flunarizine (5 mg per day) and transcutaneous supraorbital neurostimulation (tSNS) for 20 minutes daily for 3 months
Number of subjects: 154
Study 30428122 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine (5 mg per day) for 3 months
Number of subjects: 154
Study 30428122 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous supraorbital neurostimulation (tSNS) for 20 minutes daily for 3 months
Number of subjects: 154
Study 30428122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of flunarizine and tSNS
Number of subjects: 154
Study 30428122 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine group
Number of subjects: 154
Study 28324168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity with blood flow restriction (LI-BFR)
Number of subjects: 0
Study 28324168 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity (LI)
Number of subjects: 0
Study 28324168 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study 28324168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity (LI) and Low-intensity with blood flow restriction (LI-BFR)
Number of subjects: 0
Study 25555562 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (15 g)
Number of subjects: 18
Study 25555562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 23303421 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation ECT with pharmacotherapy
Number of subjects: 56
Study 23303421 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 56
Study 21121927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) 1.8 × 10(10) cfu/day
Number of subjects: 250
Study 21121927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 19665538 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg body weight of freeze dried Momordica charantia (MC50)
Number of subjects: 5
Study 19665538 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg body weight of freeze dried Momordica charantia (MC100)
Number of subjects: 5
Study 19665538 — intervention group
Group type: COMPARATOR
Intervention: No MC (placebo)
Number of subjects: 5
Study 19665538 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy expenditure
Number of subjects: 5
Study 19665538 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate oxidation rates
Number of subjects: 5
Study 19665538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid oxidation rates
Number of subjects: 5
Study 19665538 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite profile
Number of subjects: 5
Study 16054714 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 3800
Study 16054714 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score system (based on clinical, electrocardiographic and echocardiographic variables)
Number of subjects: 3800
Study 12784050 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized fiber (PMX) treatment
Number of subjects: 15
Study 12784050 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 10655988 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 466
Study 10655988 — intervention group
Group type: COMPARATOR
Intervention: Immunofluorescence
Number of subjects: 466
Study 8876775 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 50
Study 8876775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1889493 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 13080 (200 mg four times daily)
Number of subjects: 12
Study 1889493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6218793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 3
Study 6218793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 6218793 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study 31805134 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral targeted acupuncture at PC6 and ST36
Number of subjects: 6
Study 31805134 — intervention group
Group type: COMPARATOR
Intervention: bilateral non-target acupuncture at Lung-5 and Bladder-55
Number of subjects: 6
Study 31805134 — intervention group
Group type: COMPARATOR
Intervention: no acupuncture
Number of subjects: 6
Study 30042394 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIR‐V technique combined with low‐tube‐voltage (70‐kV with 50% weight)
Number of subjects: 90
Study 30042394 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIR‐V technique combined with low‐tube‐voltage (100‐kV with 30% weight)
Number of subjects: 90
Study 30042394 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIR‐V technique combined with low‐tube‐voltage (100‐kV with 50% weight)
Number of subjects: 90
Study 30042394 — intervention group
Group type: COMPARATOR
Intervention: CT venography and ultrasound results in DVT diagnosis (control group)
Number of subjects: 90
Study 26383592 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 8-methoxypsoralen (8-MOP) 2.6 mg L(-1)
Number of subjects: 20
Study 24524806 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 5 and 10 µg single dose; 5 to 30 µg once (QD) or twice daily (BID) for 5-6 weeks
Number of subjects: 0
Study 24524806 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide QD
Number of subjects: 0
Study 24524806 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide QD and BID
Number of subjects: 0
Study 24524806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22380715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered within one hour of injury
Number of subjects: 400000
Study 22380715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered within three hours of injury
Number of subjects: 400000
Study 20016796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention (PEP‐NG interface and four focused APRN visits)
Number of subjects: 240
Study 20016796 — intervention group
Group type: COMPARATOR
Intervention: Control (data collection and four routine APRN visits)
Number of subjects: 240
Study 20016796 — intervention group
Group type: EXPERIMENTAL
Intervention: APRN outcome measures
Number of subjects: 240
Study 17378785 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of propofol 10 mg/ml
Number of subjects: 77
Study 17378785 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 9.0 mg/ml
Number of subjects: 77
Study 15735182 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended intervention (24 h of education, 28 h of support groups)
Number of subjects: 216
Study 15735182 — intervention group
Group type: COMPARATOR
Intervention: Compressed intervention (16 h of education, 6 h of support groups)
Number of subjects: 216
Study 12094125 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/PRO (8.4 Mj x day(‐1) or 2010 kcal, 356 g carbohydrate, 106 g protein)
Number of subjects: 73
Study 12094125 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (isocaloric carbohydrate supplement)
Number of subjects: 73
Study 12094125 — intervention group
Group type: COMPARATOR
Intervention: CTRL (no supplement)
Number of subjects: 73
Study 12094125 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including CTRL)
Number of subjects: 73
Study 10221439 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD 1600 microg inhaled into the lungs
Number of subjects: 27
Study 10221439 — intervention group
Group type: COMPARATOR
Intervention: BUD (200 and 800 microg) and FP (200 and 800 microg) administered in the nose
Number of subjects: 27
Study 10221439 — intervention group
Group type: COMPARATOR
Intervention: FP (1500 microg) inhaled into the lungs
Number of subjects: 27
Study 10221439 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD (1600 microg) inhaled into the lungs
Number of subjects: 27
Study 7491855 — intervention group
Group type: EXPERIMENTAL
Intervention: Exluton
Number of subjects: 0
Study 7491855 — intervention group
Group type: COMPARATOR
Intervention: Multiload Cu250
Number of subjects: 0
Study 2331054 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005 mg/kg fentanyl prior to intubation
Number of subjects: 36
Study 2331054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 36
Study 342890 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5FU) with mitomycin‐C
Number of subjects: 132
Study 342890 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin‐C alone
Number of subjects: 132
Study 31409556 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.5 mg PO)
Number of subjects: 12
Study 31409556 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study 28698175 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe aortic valve calcification (AVC) at baseline
Number of subjects: 1725
Study 25673788 — intervention group
Group type: EXPERIMENTAL
Intervention: SPAZ‐IPTp (Sulfadoxine‐pyrimethamine plus azithromycin)
Number of subjects: 854
Study 25673788 — intervention group
Group type: COMPARATOR
Intervention: SPCQ (Sulfadoxine‐pyrimethamine plus chloroquine)
Number of subjects: 854
Study 23722418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (2 mg)
Number of subjects: 60
Study 23722418 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (250 μg)
Number of subjects: 60
Study 21479243 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promotion by general practitioners
Number of subjects: 4317
Study 21479243 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promotion by general practitioners (repeat prescription subgroup)
Number of subjects: 4317
Study 21479243 — intervention group
Group type: COMPARATOR
Intervention: Standard care by control GPs
Number of subjects: 4317
Study 19451428 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone plus thalidomide (100 mg/d for 72 weeks)
Number of subjects: 229
Study 19451428 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone plus thalidomide
Number of subjects: 229
Study 19451428 — intervention group
Group type: COMPARATOR
Intervention: Melphalan and prednisone plus placebo
Number of subjects: 229
Study 16939514 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin therapy (RAPA) after discontinuation of low-dose CsA
Number of subjects: 39
Study 16939514 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cyclosporine A (CsA)
Number of subjects: 39
Study 12182530 — intervention group
Group type: EXPERIMENTAL
Intervention: Promising to tell the truth
Number of subjects: 403
Study 12182530 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of lying and truth-telling
Number of subjects: 403
Study 10202164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiation and concurrent chemotherapy with fluorouracil and cisplatin (45 Gy of radiation to the pelvis plus two cycles of chemotherapy).
Number of subjects: 403
Study 10202164 — intervention group
Group type: COMPARATOR
Intervention: Pelvic radiation (45 Gy of radiation to the pelvis alone).
Number of subjects: 403
Study 7770363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber, rate responsive (DDDR) pacing
Number of subjects: 8
Study 7770363 — intervention group
Group type: COMPARATOR
Intervention: Single chamber, rate responsive (VVIR) pacing
Number of subjects: 8
Study 2161435 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ACE inhibitors (captopril or lisinopril)
Number of subjects: 0
Study 2161435 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged therapy with lisinopril (30-45 days)
Number of subjects: 0
Study 2161435 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (9 days)
Number of subjects: 0
Study 367431 — intervention group
Group type: EXPERIMENTAL
Intervention: Piloplex 3.4
Number of subjects: 9
Study 367431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine hydrochloride 4%
Number of subjects: 9
Study 367431 — intervention group
Group type: COMPARATOR
Intervention: Saline eye drops
Number of subjects: 9
Study 28442424 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over left DLPFC for 2 to 4 weeks
Number of subjects: 27
Study 28442424 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 27
Study 26847095 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 or 5 mg/kg)
Number of subjects: 26
Study 26847095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 25655102 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (7/14 regimen: one week on 120 mg/m² per day / one week off)
Number of subjects: 105
Study 25655102 — intervention group
Group type: COMPARATOR
Intervention: Arm B (3 weeks on 80 mg/m² per day / one week off)
Number of subjects: 105
Study 25655102 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MGMT-methylated tumors
Number of subjects: 105
Study 25655102 — intervention group
Group type: COMPARATOR
Intervention: Patients with MGMT-unmethylated glioblastoma
Number of subjects: 105
Study 25655102 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MGMT promoter methylation
Number of subjects: 105
Study 25655102 — intervention group
Group type: COMPARATOR
Intervention: Patients without MGMT promoter methylation
Number of subjects: 105
Study 23551856 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 234
Study 23551856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 20937044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine granules (MG) 1.5 g once-daily
Number of subjects: 305
Study 20937044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 20937044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine granules (MG)
Number of subjects: 305
Study 18390083 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (intramuscular)
Number of subjects: 132
Study 18390083 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (5 mg daily)
Number of subjects: 132
Study 18390083 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel releasing intrauterine system (LNG-IUS)
Number of subjects: 132
Study 16908464 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression in disinhibited restrainers
Number of subjects: 77
Study 16908464 — intervention group
Group type: COMPARATOR
Intervention: Thought suppression
Number of subjects: 77
Study 12505865 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day for 1 month)
Number of subjects: 16
Study 9476724 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced T1-weighted images (WI) in patients with SIH
Number of subjects: 9
Study 9476724 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings in patients with IIP
Number of subjects: 9
Study 8708427 — intervention group
Group type: EXPERIMENTAL
Intervention: High lipoprotein(a) [Lp(a)] in patients with PAD
Number of subjects: 61
Study 8708427 — intervention group
Group type: EXPERIMENTAL
Intervention: General risk factors for vascular disease
Number of subjects: 61
Study 8708427 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) as a risk indicator
Number of subjects: 61
Study 2281066 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 120
Study 2281066 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol
Number of subjects: 120
Study 2281066 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol after a prior single administration of prednisone
Number of subjects: 120